ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.
This AI chat bot was trained on drag queens, and she wants to help protect your sexual health
A few months ago, a young Black gay patient in a southern state tapped out a message on his phone that he might not have
July 2, 2024